Effects of a Two-Strain Lactobacillus Formulation (Lactobacillus rhamnosus L34 and Lactobacillus paracasei B13) on Inflammatory and Oxidative Markers, Epithelial Junction Proteins, and Fecal Microbiota in Rats with DNBS-Induced Colitis
Abstract
Inflammatory bowel disease (IBD) involves dysregulated mucosal immunity, oxidative stress, impaired epithelial barrier integrity and gut microbial dysbiosis. We evaluated a two-strain formulation of Lactobacillus rhamnosus L34 and Lactobacillus paracasei B13 in DNBS-induced colitis. Twenty-four male Sprague Dawley rats were randomised into three groups (n = 8): control, acute colitis (AC; DNBS 35 mg/0.25 mL per rat rectally on days 0 and 1), and probiotic treated (RP; 3.6 × 109 CFU daily by gavage, days −3 to 6). DNBS raised Ameho histological scores, serum TNF-α, colonic MDA and MPO positivity and lowered IL-10, occludin and claudin-1 (all p < 0.05). Relative to AC, probiotic-treated rats showed lower TNF-α (p = 0.002) and MPO positivity (p < 0.001) and higher IL-10 (p = 0.001), occludin (p = 0.014) and claudin-1 (p = 0.001). Colonic MDA and Ameho scores were numerically lower in the RP group but these differences did not reach statistical significance (p = 0.085 and p = 0.310). Serum IL-17A was unchanged. Microbial community composition differed among groups (PERMANOVA pseudo-F = 5.798, R2 = 0.356, p = 0.0001), with the probiotic-associated community distinct from both control and colitis communities; distance-based analysis detected no convergence toward the control community. The formulation attenuated inflammatory and barrier outcomes and altered microbiota composition without restoring it.